Farxiga (Dapagliflozin) Indications
Farxiga is FDA-approved for four distinct clinical indications that prioritize reducing cardiovascular death, heart failure hospitalizations, and kidney disease progression, with glycemic control being only one of its uses. 1
FDA-Approved Indications
Based on the official FDA labeling, Farxiga is indicated for:
1. Chronic Kidney Disease (CKD) at Risk of Progression
- To reduce the risk of sustained eGFR decline, end-stage kidney disease (ESKD), cardiovascular death, and hospitalization for heart failure in adults with CKD at risk of progression 1
- Dose: 10 mg once daily 1
- This indication applies regardless of diabetes status 2
- The DAPA-CKD trial demonstrated a 44% reduction in the composite outcome of sustained eGFR decline ≥50%, ESKD, or renal/CV death (HR 0.56,95% CI 0.45-0.68) 2
Important limitation: Not recommended for polycystic kidney disease or patients requiring/with recent immunosuppressive therapy for kidney disease 1
2. Heart Failure (Any Diabetes Status)
- To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure 1
- Dose: 10 mg once daily 1
- This applies to heart failure with reduced ejection fraction (HFrEF), with or without diabetes 2, 3
- The DAPA-HF trial showed a 26% reduction in worsening HF or CV death (HR 0.74,95% CI 0.65-0.85) 4
- All-cause mortality was reduced by 17% 3
3. Type 2 Diabetes with Cardiovascular Risk
- To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and either established cardiovascular disease OR multiple cardiovascular risk factors 1
- Dose: 10 mg once daily 1
- This is a cardiovascular risk reduction indication, not primarily for glucose control 2
4. Glycemic Control in Type 2 Diabetes
- As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes 1
- Starting dose: 5 mg once daily, can increase to 10 mg for additional glycemic control 1
Critical Limitations and Contraindications
Renal Function Restrictions
The FDA label provides specific eGFR cutoffs that vary by indication 4:
For glycemic control in type 2 diabetes:
- Not recommended if eGFR <45 mL/min/1.73 m² (likely ineffective based on mechanism) 1
For heart failure indication:
For CKD indication:
- Can initiate if eGFR ≥25 mL/min/1.73 m² 5
- May continue if eGFR drops below 25 in patients already on therapy 5
Absolute contraindications:
Common Pitfalls to Avoid
Volume depletion: Assess and correct volume status before initiating, especially in elderly patients or those on diuretics 2, 1
Surgical planning: Discontinue at least 3 days before planned surgery to prevent postoperative ketoacidosis 4
Genital mycotic infections: Most common adverse effect (10-15% risk in women, higher in uncircumcised men). Usually manageable with antifungals without discontinuation 2
Temporary eGFR decline: May see up to 15% reduction in eGFR initially, which typically resolves within 1-3 months 2
Clinical Context from Guidelines
The 2021 Canadian Heart Failure guidelines provide strong recommendations (all with high-quality evidence) for dapagliflozin across multiple populations 2:
- HFrEF patients (with or without diabetes) to improve symptoms, quality of life, and reduce HF hospitalization/CV mortality
- Type 2 diabetes with atherosclerotic CVD to reduce HF hospitalization and death
- Type 2 diabetes patients >50 years with additional CV risk factors to reduce HF hospitalization
- Albuminuric renal disease (with or without diabetes) to reduce HF hospitalization and progression of renal disease
The 2022 AHA/ACC/HFSA Heart Failure guidelines recommend SGLT2 inhibitors like dapagliflozin as foundational therapy in HFrEF, noting cost-effectiveness with costs per QALY between $60,000-$90,000 3.